According to the Municipal Commission of Economy and Information Technology, on February 28th, the National Drug Administration (NMPA) issued a "Drug Registration Certificate" to Shanghai Shengdi Pharmaceutical Co., Ltd., which independently developed the PD-L1 inhibitor Adebelizumab (trade name: Arili). This drug is the first domestically developed PD-L1 inhibitor approved for small cell lung cancer indications in China, bringing patients a new treatment option. Since January 29th, when Deuteromidevir Hydrobromide Tablets (product name: Mindavir) were conditionally approved for sale, two Class 1 innovative drugs have been approved for sale in this city in the first quarter of this year; Since 2019, a total of 17 Class 1 innovative drugs and 23 Class 3 innovative medical devices have been approved.